검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lenvatinib |
Overview Company | Academic and Community Cancer Research United |
Overview Modality | ADC |
Overview Target | Solid Tumor |
Overview Indication | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma |
PK/PD Half-life | 28 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse, Rat, Rabbit, Human |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | Hepatotoxicity : Monitor liver function prior to treatment and periodically during treatmen |
Clinical Primary efficacy | ORR 58% |
Clinical ORR | 58.0% |
Clinical Result source | ClinicalTrials.gov NCT04662710 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Lenvatinib |
Overview Company | Academic and Community Cancer Research United |
Overview Modality | ADC |
Overview Target | Solid Tumor |
Overview Indication | Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | targeted agents, including epidermal growth factor receptor, anaplastic lymphoma kinase, BCR-ABL, vascular endothelial growth factor receptor |
MoA Biomarker | biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma |
PK/PD Half-life | 28 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse, Rat, Rabbit, Human |
Toxicology Animal (cat.) | Mouse, Rat, Dog |
Toxicology Major finding | Hepatotoxicity : Monitor liver function prior to treatment and periodically during treatmen |
Clinical Primary efficacy | ORR 58% |
Clinical ORR | 58.0% |
Clinical Result source | ClinicalTrials.gov NCT04662710 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교